AMAG Pharma acquires North American rights from Palatin Technologies Inc. to Rekynda (bremelanotide) to treat hypoactive sexual desire disorder.
AMAG Pharmaceuticals, Inc. together with Palatin Technologies, Inc. announced they have entered into an agreement for exclusive North American rights to develop and commercialize Rekynda (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, that has successfully completed two Phase III trials.
The anticipated filing date in the U.S. for a new drug application (NDA) for Rekynda is in early 2018, with an anticipated approval and launch by early 2019.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins